ERBB2 and gastric cancer: A pooled HR analysis highlighted that first-line ICI immunotherapy does not reduce the risk of disease progression and death in non-HER2-positive/HER2-negative advanced or metastatic GC or GEJC with a negative expression of PD-L1 or a low expression of it.